Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4996 -  Analysis of PD-L1 Expression in Patients with Gastrointestinal Stromal Tumors

Date

11 Sep 2017

Session

Poster display session

Presenters

Ana Beatriz Kinupe Abrahao

Citation

Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387

Authors

A.B. Kinupe Abrahao1, R. Jamani2, E. Hsieh3, Y. Ko2

Author affiliations

  • 1 Medical Oncology, Sunnybrook Odette Cancer Center, Sunnybrook HSC, M4N 3M5 - Toronto/CA
  • 2 Medical Oncology, Sunnybrook Odette Cancer Centre, M4N 3M5 - Toronto/CA
  • 3 Anatomic Pathology, Sunnybrook Odette Cancer Centre, M4N 3M5 - Toronto/CA
More

Resources

Abstract 4996

Background

The immune system is believed to have an important role in solid tumor progression. The development of monoclonal antibodies targeting immune checkpoints, such as programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1), have revolutionized the treatment of some cancers. Recent efforts have attempted to elucidate the relevance of the PD-1/PD-L1 pathway in gastrointestinal stromal tumors (GIST).

Methods

Formalin-fixed, paraffin-embedded specimens were obtained from resected GIST at Sunnybrook Health Sciences Centre between March 2008 and August 2015. PD-L1 analysis was based off a tissue microarray of the cases using the Roche Ventana SP263 antibody. Each case had 1mm cores taken from different areas of the tumor block. Normal controls used for PD-L1 were placenta and tonsil (epithelial and inflammatory). CD117 was assessed via immunohistochemistry in all tumor specimens.

Results

Of twenty-nine patients who underwent surgical resection, eight had insufficient tumor tissue for analysis, and three cases were excluded due to CD117 negativity after preoperative imatinib treatment, leaving 18 patients for analysis. Three of these 18 cases were positive for PD-L1 expression: 2 patients with moderate PD-L1 staining in 85% of the stromal cells and 1 with weak staining in 15% of the stromal cells. Fifteen patients were negative for PD-L1 expression. Analysis of PD-L1 expression in tumor-infiltrating lymphocytes was not feasible due to the lack of inflammatory cells in tumor environment. The patients whose samples had significant PD-L1 expression had gastric primaries, with tumour size  512 31 2

Conclusions

In this cohort, PD-L1 may be a favorable prognostic biomarker. Further studies to examine the clinical benefit of immunotherapy in GIST patients with or without PD-L1 expression are warranted.

Clinical trial identification

Legal entity responsible for the study

Ana Beatriz Kinupe Abrahao

Funding

Glenita Mungcal GIST Research Award from the Life Raft Group Canada

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.